目的观察国产唑来膦酸(因力达)治疗乳腺癌骨转移的临床疗效和不良反应。方法国产唑来膦酸4 mg加入0.9%生理盐水100 mL静脉滴注15 min,1次/4周,持续治疗6个月后评估疗效及不良反应。结果唑来膦酸治疗患者骨痛、骨转移病灶、生活活动能力的有效率分别为83.3%、66.7%、75.0%;血液指标异常例数较治疗前有所减少,异常率有下降趋势,但治疗前后比较无统计学差异;不良反应为发热1例(4.2%),肌肉关节酸痛2例(8.3%),全身及末梢水肿1例(4.2%),经对症治疗后消失。结论国产唑来膦酸(因力达)治疗乳腺癌骨转移疗效肯定,不良反应发生率低,是临床治疗乳腺癌骨转移的优选方法。 Objective To observe the clinical efficacy and adverse reactions of domestic zoledronic acid (Reeda) in the treatment of breast cancer with bone metastases. Methods Domestically administered zoledronic acid 4 mg was intravenously infused with 100 mL of 0.9% physiological saline for 15 minutes once a week for 4 weeks. The efficacy and adverse reactions were evaluated after 6 months of continuous treatment. Results The effective rates of zoledronic acid in treating patients with bone pain, bone metastases, and living activity were 83.3%, 66.7%, and 75.0%, respectively. The number of abnormal blood samples decreased compared with that before treatment, and the abnormal rate decreased. There was no statistical difference before and after treatment. The adverse reactions were fever in 1 case (4.2%), muscle and joint pain in 2 cases (8.3%), systemic and peripheral edema in 1 case (4.2%), disappeared after symptomatic treatment. Conclusion The domestically produced zoledronic acid (Relita) is effective in the treatment of bone metastases from breast cancer and has a low incidence of adverse reactions. It is the preferred method for clinical treatment of bone metastases in breast cancer.